A new study has uncovered a molecular mechanism by which rice cells perceive viral infections and initiate antiviral response ...

The recent approvals and robust pipeline activity are expected to fuel the market of molecular glues in the 7MM during the forecast period 2025-2034 due to factors like improved diagnosis, treatment ...

DelveInsight's Molecular Glues Market Insights report includes a comprehensive understanding of current treatment practices, ...

Orphan Drug Designation follows positive Phase 1 data presented at the 12th International Workshop on Waldenström MacroglobulinemiaFirst-in-class ...

This new cryo-EM structure represents a remarkable advance in our understanding of how human PINK1 is stabilized” said ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, the next ...

Shenzhen Zhongge Biotechnology Co. Ltd. has identified proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to an interleukin-1 ...

Katalytic Therapeutics Inc. has divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to a phosphodiesterase PDE4-targeting ...

Nurix's wholly owned, clinical stage pipeline includes degraders of Bruton's tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), ...

UBE3A is an E3 ubiquitin ligase encoded by an imprinted gene whose maternal deletion or duplication leads to distinct neurodevelopment disorders Angelman and Dup15q syndromes. Despite the known ...

Parkin, an E3 ubiquitin ligase, is recruited to the outer mitochondrial membrane through PINK1 phosphorylation, promoting mitochondrial degradation processes. OMA1 is a mitochondrial inner ...